Evrys Bio

[Available On-Demand]
Evrys Bio was founded on breakthrough discoveries from Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the patient’s cellular intrinsic immunity to fight viral infections. Our vision is to develop safe, first-in-class antivirals that address the problem of acquired drug-resistance and provide unique broad-spectrum treatment options. Because Evrys Bio products address the infectious disease condition, as opposed to targeting a specific virus-type, the practice of medicine will be transformed. Imagine being prescribed a safe, broad-spectrum antiviral based on your symptoms presentation, and perhaps, without the need for diagnostic confirmation of infecting virus. These highly-innovative products are early-stage, yet we are making great progress in solving real clinical challenges and unmet medical need.
Company Type:
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
EV-100
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO
Evrys Bio